BC
CADL icon

Birchview Capital’s Candel Therapeutics CADL Stock Holding History

Birchview Capital’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$294K Hold
60,000
– – 0.17% 62
2025
Q4 		$339K Hold
60,000
– – 0.2% 59
2025
Q3 		$306K Hold
60,000
– – 0.23% 59
2025
Q2 		$304K Hold
60,000
– – 0.3% 51
2025
Q1 		$339K Hold
60,000
– – 0.29% 40
2024
Q4 		$521K Buy
+60,000
New +$355K 0.42% 31

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Birchview Capital's CADL Position: Q1 2026 in Review

Birchview Capital held its Candel Therapeutics (CADL) position steady in Q1 2026 at 60,000 shares worth $294K. The position accounts for 0.17% of the portfolio, ranked #62.

Birchview Capital first reported a position in CADL in Q4 2024 and has held it in 6 quarters since. The position peaked at $521K in Q4 2024. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Birchview Capital held 60,000 shares of Candel Therapeutics worth $294K as of Q1 2026.
  • Birchview Capital left its Candel Therapeutics share count unchanged in Q1 2026.
  • Candel Therapeutics made up 0.17% of Birchview Capital's portfolio in Q1 2026, its #62 holding.
  • Birchview Capital first reported a position in Candel Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Birchview Capital's Candel Therapeutics position peaked at $521K in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.